Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `jetpack` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /var/www/wp-includes/functions.php on line 5835
approvals – Force Pharma Capital
Skip to content
Force Pharma Capital
Force Pharma Capital
Life Science Consulting, Business Development and Recruiting/Staffing
  • Home
  • Services
  • Pharmaceutical Blog
    • RLD
    • Excipients
    • Equipment
    • Health Technology
    • Regulatory Fees
  • Contact Us
  • FAQ
  • Portfolio

Tag: approvals

FDA approves first drug for treatment of peanut allergy for children

February 1, 2020 Blogger

FDA approves first drug for treatment of peanut allergy for children — Read on s2027422842.t.en25.com/e/es This is a huge achievement…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa, technology

FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer

January 24, 2020 Blogger

FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer — Read on s2027422842.t.en25.com/e/es

Continue Reading →

Posted in: Health Technology Filed under: approvals, pdufa

First Generic Drug Approvals | FDA

January 11, 2020 Blogger

Each year, FDA’s Center for Drug Evaluation and Research (CDER) approves a wide range of new drug products. FDA provides…

Continue Reading →

Posted in: Uncategorized Filed under: approvals, FDA, gdufa

FDA grants accelerated approval to first targeted treatment for rare Duchenne Muscular Dystrophy (DMD) mutation – Drug Information Update

December 13, 2019 Blogger

FDA grants accelerated approval to first targeted treatment for rare Duchenne Muscular Dystrophy (DMD) mutation – Drug Information Update —…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa

FDA Updates List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic

Blogger

FDA Updates List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic — Read on s2027422842.t.en25.com/e/es

Continue Reading →

Posted in: Uncategorized Filed under: approvals, FDA, gdufa

Drug Trials Snapshots BRUKINSA | FDA

December 1, 2019 Blogger

Drug Trials Snapshots — Read on www.fda.gov/drugs/resources-information-approved-drugs/drug-trials-snapshots-brukinsa More inhibitors for oncology.

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa

FDA approves new breakthrough therapy for cystic fibrosis | FDA

October 21, 2019 Blogger

FDA approves breakthrough therapy Trikafta for patients 12 and older with cystic fibrosis who have at least one F508del mutation…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, fixed dose combination, pdufa, technology

FDA approves new treatment for patients with migraine | FDA

October 11, 2019 Blogger

The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine…

Continue Reading →

Posted in: Uncategorized Filed under: approvals, pdufa

Drug Trials Snapshots: IBSRELA | FDA

September 27, 2019 Blogger

IBSRELA is a treatment for Irritable bowel syndrome with constipation The disease has two variants, with diarrhea and with constipation…

Continue Reading →

Posted in: Health Technology Filed under: approvals, pdufa

DAURISMO for Acute Myeloid Leukemia

September 22, 2019 Blogger

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa

Post navigation

Page 1 of 3
1 2 3 Next →

Recent Posts

  • Most Recent Changes to the IID Database | FDA
  • The History, Benefits of Pharmaceutical REMS Programs
  • FDA approves first drug for treatment of peanut allergy for children

Recent Comments

  • flower bouquet delivery online on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma
  • cheap flowers online same day delivery on Trending News Today: Investigational Long-Acting HIV Injection Shows Efficacy in Study
  • flower arrangements for baby shower girl on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Archives

  • August 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • November 2018

Follow Us

Contact Us

  • Email
    forcepharma@icloud.com
  • Phone
    732-702-1824
  • Address
    265 Route 34 Lower Level, Colts Neck, New Jersey, 07722
Copyright © 2018 Force Pharma Capital